Genotypic diagnosis of extra pulmonary tuberculosis – CBNAAT a novel tool

 

Gour Sanjay M^1*, Munje Radha P², Ninu P Babu³, Muley Sushant⁴, Atram Jitesh⁴

 

 ¹Associate Professor, ²Professor and HOD, ³Jr. Resident, ⁴Assistant  Professor, Department  of Respiratory Medicine, Indira Gandhi Government Medical College, Nagpur, Maharashtra, INDIA.

Email: dr_smg2004@yahoo.com

 

Abstract              Objectives: To evaluate the utility of CBNAAT in detecting MTB  in suspected extrapulmonary tuberculosis smear negative cases. To see for Rifampicin resistance amongst CBNAAT MTB positive cases. Methods: Retrospective record based analysis. Study period: 6 months October 2016 to march 2017. Results: Retrospective analysis of 267 samples done. Most of the cases were of age group 20 to 50 years of age. Maximum cases were in the age group 21-30 years of age with MTB detected in 13(16.88%) cases. MTB was detected in 47(17.6% )samples. Of these 47 samples, 44(93.6%) were sensitive to rifampicin and 3(6.38%) were resistant to rifampicin. 174(65.16%) were males and 93(34.83%) were females. Of 174 males, MTB was detected in 26(14.9%) and out of 93 females, MTB was detected in 21(22.5%). Conclusion: CBNAAT is a useful test to confirm presence of MTB with simultaneous detection of rifampicin resistance in EPTB AFB smear negative cases. This has an impact on treatment and outcome as all presumptive cases have a confirmed diagnosis.

Key Words: Genotypic diagnosis, pulmonary tuberculosis.